These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 32926384)

  • 1. Methods for Measuring CRISPR/Cas9 DNA Cleavage in Cells.
    Cromwell CR; Jovel J; Hubbard BP
    Methods Mol Biol; 2021; 2162():197-213. PubMed ID: 32926384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Assays for Comparing the Specificity of First- and Next-Generation CRISPR/Cas9 Systems.
    Cromwell CR; Hubbard BP
    Methods Mol Biol; 2021; 2162():215-232. PubMed ID: 32926385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
    Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
    Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency.
    Chung CH; Allen AG; Sullivan NT; Atkins A; Nonnemacher MR; Wigdahl B; Dampier W
    Mol Ther; 2020 Jan; 28(1):19-28. PubMed ID: 31672284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling Genome-Wide Specificity of CRISPR-Cas9 Using Digenome-Seq.
    Kim D; Kim JS
    Methods Mol Biol; 2021; 2162():233-242. PubMed ID: 32926386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
    Moreb EA; Hutmacher M; Lynch MD
    CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system.
    Matson AW; Hosny N; Swanson ZA; Hering BJ; Burlak C
    PLoS One; 2019; 14(12):e0226107. PubMed ID: 31821359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of target specificity of CRISPR-Cas12a by using a chimeric DNA-RNA guide.
    Kim H; Lee WJ; Oh Y; Kang SH; Hur JK; Lee H; Song W; Lim KS; Park YH; Song BS; Jin YB; Jun BH; Jung C; Lee DS; Kim SU; Lee SH
    Nucleic Acids Res; 2020 Sep; 48(15):8601-8616. PubMed ID: 32687187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bridge helix of Cas12a imparts selectivity in cis-DNA cleavage and regulates trans-DNA cleavage.
    Parameshwaran HP; Babu K; Tran C; Guan K; Allen A; Kathiresan V; Qin PZ; Rajan R
    FEBS Lett; 2021 Apr; 595(7):892-912. PubMed ID: 33523494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila.
    Gratz SJ; Ukken FP; Rubinstein CD; Thiede G; Donohue LK; Cummings AM; O'Connor-Giles KM
    Genetics; 2014 Apr; 196(4):961-71. PubMed ID: 24478335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cleavage-Responsive Stem-Loop Hairpin for Assaying Guide RNA Activity.
    deBoer TR; Wauford N; Chung JY; Torres Perez MS; Murthy N
    ACS Chem Biol; 2018 Feb; 13(2):461-466. PubMed ID: 29381046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
    Haeussler M; Concordet JP
    J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A catalogue of biochemically diverse CRISPR-Cas9 orthologs.
    Gasiunas G; Young JK; Karvelis T; Kazlauskas D; Urbaitis T; Jasnauskaite M; Grusyte MM; Paulraj S; Wang PH; Hou Z; Dooley SK; Cigan M; Alarcon C; Chilcoat ND; Bigelyte G; Curcuru JL; Mabuchi M; Sun Z; Fuchs RT; Schildkraut E; Weigele PR; Jack WE; Robb GB; Venclovas Č; Siksnys V
    Nat Commun; 2020 Nov; 11(1):5512. PubMed ID: 33139742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Genome Editing with CRISPR-Cas9.
    Rahman S; Ikram AR; Azeem F; Tahir Ul Qamar M; Shaheen T; Mehboob-Ur-Rahman
    Methods Mol Biol; 2024; 2788():355-372. PubMed ID: 38656525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Disruption Using Chemically Modified CRISPR-Cpf1 RNA.
    McMahon MA; Rahdar M
    Methods Mol Biol; 2021; 2162():49-60. PubMed ID: 32926377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.